Sanofi would begin its human clinical trials of its second COVID-19 vaccine candidate
French pharmaceutical company Sanofi on Friday announced the launch of human clinical trials of its second COVID-19 vaccine, with its first COVID-19 vaccine still in the testing phase after having fallen behind in development.
Translate Bio and Sanofi were developing the COVID-19 vaccine based on messenger RNA (mRNA) technology.
The Phase 1 and 2 clinical trials aimed to verify that the said vaccine wasn’t dangerous and to give initial information on its effectiveness, while the Phase 3 clinical trial would be carried out on many more patients in order to determine its effectiveness.
GMA News Online reported that the first clinical trials would include 415 people, with inital results expected in the third quarter of 2021.
Messenger RNA (mRNA) technology was also used in the Pfizer-BioNTech and Moderna COVID-19 vaccines, already authorized in the United States, the European Union, and elsewhere.
It was the second vaccine developed by Sanofi against the coronavirus disease.
An earlier candidate, developed with GSK, was recombinant protein-based, but its development was several months behind schedule and testing was only in phase 2 clinical trials, with hopes to launch it in late 2021.
Sanofi had also agreed to help produce COVID-19 vaccines developed by Johnson & Johnson and Pfizer.